Huyabio: First Patient Enrolled in Pivotal Clinical Trial of Ipatasertib for HCC Treatment

1 day ago / Read about 0 minute

Author：小编

Huyabio proudly announces that its subsidiary, Shanghai Huyabiopharma, has successfully dosed the first patient in the pivotal clinical trial of ipatasertib, a highly selective small molecule FGFR4 inhibitor designed for the treatment of hepatocellular carcinoma (HCC). In May 2025, ipatasertib received Breakthrough Therapy Designation from the China National Medical Products Administration, marking it as the pioneering drug to utilize targeted molecular biomarkers for precision medicine in HCC therapy.

Previous page：Publication of vivo's Patent on "Terminal Message ...

Next page：SZSE Adds Contemporary Amperex Technology Co. Limi...

Return to List

Hot Reading

2 day ago

Intel's new ‘no frills, just thrills’ budget gaming CPU leaked

2 day ago

People Don't Realize Meta's AI App Is Publicly Blasting Their Humiliating Secrets to the World

2 day ago

The App Store’s new AI-generated tags are live in the beta

2 day ago

AMD quietly launches a budget gaming beast